Hepatitis C Virus therapeutics development landscape continues to inflate

Research and Markets (http://www.researchandmarkets.com/research/f6bf5e/hepatitis_c_virus) has announced the addition of the "Hepatitis C Virus And Therapeutics - A Global Update of Market Trends & Opportunities" report to their offering.

Bucking the trend witnessed for all these years of meager clinical outcomes owing to lack of superior therapies, research & development in hepatitis C virus therapeutics market is on the verge of a major breakthrough.

The Hepatitis C Virus (HCV) therapeutics development landscape continues to inflate and currently possesses three compounds in Phase III clinical studies, several novel therapies in Phase II and Phase I pipeline, and numerous new compounds in animal-stage study and research stages.

Along with immunomodulators, long acting/oral interferons, and direct acting anti-viral therapies, new compounds represented by several other drug categories, including Polymerase/Protease Inhibitors, MicroRNA, TLR9 agonists, NS5A Inhibitors, Cyclophilin inhibitors, A3AR Agonists, and vaccines among others, would be successfully developed to expand the scope of HCV treatment.

These and other market data and trends are presented in "Hepatitis C Virus And Therapeutics: A Global Update of Market Trends & Opportunities" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

http://www.researchandmarkets.com/research/f6bf5e/hepatitis_c_virus